Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years

June 27th 2024

Liso-cel continued to show improved disease control and EFS and PFS vs SOC in the second-line treatment of patients with large B-cell lymphoma.

Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL

June 27th 2024

Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.

FDA Grants Accelerated Approval to Epcoritamab for Relapsed/Refractory Follicular Lymphoma

June 26th 2024

The FDA has granted accelerated approval to epcoritamab-bysp (Epkinly) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

Valemetostat Tosilate Approved in Japan for R/R PTCL

June 24th 2024

Valemetostat tosilate has been approved by the Japan Ministry of Health, Labor and Welfare for the treatment of patients with relapsed/refractory PTCL.

China’s NMPA Grants Priority Review to Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

June 20th 2024

Tafasitamab plus lenalidomide has been granted priority review in China for transplant-ineligible, relapsed/refractory diffuse large B-cell lymphoma.

Battiwalla Talks Bispecific Antibodies, BTK Inhibitors, and Emerging Therapies in Hematologic Malignancies

June 19th 2024

Minoo Battiwalla, MD, discusses the role of bispecific antibodies as an alternative to CAR T-cell therapies in NHL, treatment strategies for aggressive follicular lymphomas, and more.

Golidocitinib Green Lit by China’s NMPA for Relapsed/Refractory PTCL

June 19th 2024

Golidocitinib has received approval from China’s NMPA for relapsed/refractory peripheral T-cell lymphoma.

Dr Svoboda on the Investigation of huCART19-IL18 in Relapsed/Refractory Lymphoma

June 18th 2024

Jakub Svoboda, MD, discusses the investigation of huCART19-IL18 in patients with relapsed/refractory lymphomas that have progressed.

Glofitamab Plus Gemcitabine/Oxaliplatin Shows Survival Benefit in Transplant-Ineligible R/R DLBCL

June 15th 2024

Adding fixed-duration glofitamab-gxbm (Columvi) to gemcitabine and oxaliplatin led to a statistically significant and clinically meaningful improvement in survival vs rituximab (Rituxan) plus gemcitabine/oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.

CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL

June 14th 2024

The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.

Englumafusp alfa/Glofitamab Combo Shows Early Responses in R/R Aggressive non-Hodgkin Lymphoma

June 14th 2024

Englumafusp alfa plus glofitamab showed activity and tolerability in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Dr Matasar on the Design of the OLYMPIA-3 Trial in DLBCL

June 13th 2024

Matthew Matasar, MD, discusses the design of the phase 3 OLYMPIA-3 trial of odronextamab plus CHOP in treatment-naive intermediate- or high-risk DLBCL.

CAR T-Cell Therapy vs Bispecific Antibodies: Picking an Approach in R/R DLBCL

June 13th 2024

Marie Hu, MD, discusses considerations for the use of CAR T-cell therapy and bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma.

Dr Neelapu on Streamlining the Delivery of CAR T-Cell Therapy in Lymphoma

June 12th 2024

Sattva S. Neelapu, MD, discusses processes that have been adopted to streamline the delivery of CAR T-cell therapy to patients with lymphoma.

Dr Neelapu on Clinical Trial Data With CAR T-Cell Therapy in Lymphoma

June 11th 2024

Sattva S. Neelapu, MD, discusses key clinical trial data that support the use of CAR T-cell therapy in standard practice for patients with lymphoma.

Dr Vose on the Investigation of Epcoritamab in Relapsed/Refractory Follicular Lymphoma

June 11th 2024

Julie M. Vose, MD, MBA, discusses the investigation of epcoritamab in relapsed/refractory follicular lymphoma.

Dr Nayak on the Investigation of Axi-Cel in CNS Lymphoma

June 11th 2024

Lakshmi Nayak, MD, discusses the investigation of axi-cel in patients with relapsed/refractory primary and secondary CNS lymphoma.

Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas

June 11th 2024

Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma.

Dr Svoboda on the Efficacy of Armored huCART19-IL18 in R/R Lymphoma

June 10th 2024

Jakub Svoboda, MD, discusses outcomes with armored huCART19-IL18 in patients with previously treated relapsed/refractory lymphomas that have progressed.

Tucidinostat Plus R-CHOP Improves EFS in DLBCL Expressing MYC and BCL2

June 2nd 2024

Tucidinostat plus R-CHOP improved efficacy and was safe in previously untreated DLBCL expressing MYC and BCL2.